DF/HCC Program Affiliation

Breast Cancer

Research Abstract

My research focuses on tailoring clinical treatments to specific subpopulations of patients with breast cancer. The goal is two fold: 1. Identify therapies and supportive care most likely to be effective and/or essential and 2. Limit treatment and toxicity to only those who will benefit. We have recently performed and published the first systematic review of inflammatory breast cancer, a rare subtype that has a unique biology and clinical presentation, for which unique treatments may be indicated. In addition, we have utilized large data sets from completed phase III adjuvant trials, kindly provided by the Eastern Cooperative Oncology Group, to create a patient specific predictive model to predict the need for cytokine support to prevent dose reductions. Past collaborations have contributed to phase III studies on the role of stem cell transplantation in metastatic breast cancer (NEJM) and the role of docetaxel in stage II-IV breast cancer (JCO)

Publications

• Kim T, Lau J, Erban J.Lack of uniform diagnostic criteria for inflammatory breast cancer limits interpretation of treatment outcomes: a systematic review.Clin Breast Cancer 2006 Dec;7(5):386-95.
  17239263
• Erban JK, Lau J.On the toxicity of chemotherapy for breast cancer--the need for vigilance.J Natl Cancer Inst 2006 Aug 16;98(16):1096-7.
  16912256
• Jones SE, Erban J, Overmoyer B, Budd GT, Hutchins L, Lower E, Laufman L, Sundaram S, Urba WJ, Pritchard KI, Mennel R, Richards D, Olsen S, Meyers ML, Ravdin PM.Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer.J
  16110015
• Savvides P, Terrin N, Erban J, Selker HP.Development and validation of a patient-specific predictive instrument for the need for dose reduction in chemotherapy for breast cancer: a potential decision aid for the use of myeloid growth factors.Support Care
  12720075
• Bell DW, Erban J, Sgroi DC, Haber DA.Selective loss of heterozygosity in multiple breast cancers from a carrier of mutations in both BRCA1 and BRCA2.Cancer Res 2002 May 15;62(10):2741-3.
  12019146
• Stadtmauer EA, O'Neill A, Goldstein LJ, Crilley PA, Mangan KF, Ingle JN, Brodsky I, Martino S, Lazarus HM, Erban JK, Sickles C, Glick JH.Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplant
  10760307